Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) FCF Margin (2016 - 2025)

China Pharma Holdings filings provide 16 years of FCF Margin readings, the most recent being 5.98% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1865.0% to 5.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.26%, a 945.0% increase, with the full-year FY2025 number at 0.26%, up 1007.0% from a year prior.
  • FCF Margin hit 5.98% in Q4 2025 for China Pharma Holdings, up from 31.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 52.11% in Q3 2023 to a low of 72.04% in Q1 2023.
  • Median FCF Margin over the past 5 years was 7.48% (2021), compared with a mean of 8.95%.
  • Biggest five-year swings in FCF Margin: tumbled -5955bps in 2022 and later surged 5381bps in 2023.
  • China Pharma Holdings' FCF Margin stood at 7.1% in 2021, then surged by 395bps to 20.95% in 2022, then plummeted by -106bps to 1.25% in 2023, then soared by 2071bps to 24.62% in 2024, then plummeted by -76bps to 5.98% in 2025.
  • The last three reported values for FCF Margin were 5.98% (Q4 2025), 31.42% (Q3 2025), and 28.6% (Q2 2025) per Business Quant data.